Cambridge Healthtech Institute Announces Featured Presentations at Circulating Cell-Free DNA

NEEDHAM, Mass. - Nov. 18, 2015 - PRLog -- At Cambridge Healthtech Institute’s Third Annual Circulating Cell-Free DNA, leading researchers from academia and industry will come together to address advances as well as existing challenges in this rapidly growing field. This year’s event will place emphasis on early detection, clinical validation of assay sensitivity and specificity, and establishing standards for cfDNA.

Sessions Include:

·         Clinical Validation of Assay Sensitivity and Specificity

·         Clinical Trial Data

·         Applicability of CFDNA in Early Stage Disease

·         Assessment of CFDNA Technologies

·         Establishing Standards

Speakers Include:

Nishant Agrawal, M.D., Associate Professor, Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine

Chetan Bettegowda, M.D., Ph.D., Assistant Professor, Neurological Surgery, Johns Hopkins University School of Medicine

Maximilian Diehn, M.D., Ph.D., Assistant Professor, Radiation Oncology, Stanford University

Mark G. Erlander, Ph.D., CSO, Trovagene

Tim Forshew, Ph.D., Head, Technology Development, Inivata, Ltd.

Timothy Harkins, President & CEO, Swift Biosciences

Dave S.B. Hoon, Ph.D., Director, Molecular Oncology and Sequencing Center, John Wayne Cancer Institute, Providence Health Care

Raghu Kalluri, M.D., Ph.D., Professor, Department of Cancer Biology, Division of Basic Science Research, The University of Texas MD Anderson Cancer

Chris Karlovich, Ph.D., Principal Scientist, Molecular Diagnostics, Clovis Oncology

Raj Krishnan, Ph.D., CEO, Biological Dynamics, Inc.

Rebecca Leary, Ph.D., Lab Head & Research Investigator, Genomics Group, Next Generation Diagnostics, Novartis

Muhammed Murtaza, Research Assistant Professor, Co-Leader, Center for Non-Invasive Diagnostics, Translational Genomics Research Institute

John Palma, Ph.D., Director, Medical Affairs, Roche

Abhijit Patel, M.D., Ph.D., Assistant Professor, Yale University School of Medicine

Cloud P. Paweletz, Ph.D., Head, Translational Research Laboratory; Biomarker Lead, Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute

Katherine Richardson, Ph.D., Vice President, Research & Development,Transgenomic, Inc

Adrian G. Sacher, M.D., Clinical Fellow, Medicine, Dana-Farber Cancer Institute

John J. Sninsky, Ph.D. CSO, CareDx

Grace Zhao, Ph.D., Co-Founder and Director, Research, AccuraGen

Early registration discounts are available until December 4, 2015. To view the entire conference agenda and to register, please visit http://www.triconference.com/Circulating-DNA.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.